Business Standard

Sunday, December 22, 2024 | 10:49 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Carlyle Group to buy 74% in SeQuent Scientific for over Rs 1,500 crore

The transaction is being done through an equity purchase stake that values each share at Rs 86.

Need cash now? Avoid taking a personal loan for discretionary purchases
Premium

Carlyle has invested around $2.5 billion in India over the past two decades and key transactions have included investments in SBI Life, SBI Cards, Medanta Medicity, and Metropolis Healthcare.

Pavan Lall Mumbai
Private equity player The Carlyle Group has signed up to acquire a majority 74 per cent stake in Mumbai-headquartered animal health care company SeQuent Scientific for over Rs 1,500 crore.

The transaction is being done through an equity purchase stake that values each share at Rs 86. The deal will be executed through two investment vehicles — CA Harbor Investments, affiliated entity of CAP V Mauritius, which is an affiliated entity of Carlyle. The deal is first control investment in an Indian publicly-listed company for Carlyle.
 
Carlyle's global portfolio in the animal nutrition and health care sectors include Manna Pro

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in